Fresenius Medical Care announced a multinational study published in the Journal of the American Society of Nephrology.
High-volume hemodiafiltration (HDF) showed a 28% lower relative risk of all-cause mortality compared to conventional high-flux hemodialysis. Fresenius is a leading provider of this treatment technology.
The research analyzed nearly 20,000 dialysis patients across eight European countries.
These findings support the company's strategy to establish high-volume HDF as a modern standard of care. Fresenius plans to expand access to this technology in the United States. The publication aims to drive broader adoption of the company's advanced dialysis systems.